Scott Gottlieb is an American physician who served as the 23rd Commissioner of the U.S. Food and Drug Administration. Dr. Gottlieb’s work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping health care delivery, and expanding consumer choice and safety. He is a resident fellow at the American Enterprise Institute, a member of the board of directors of drug maker Pfizer, a member of the board of directors of the biotech company Illumina, a contributor to the cable financial news network CNBC, and a partner at the venture capital firm New Enterprise Associates. Since March 2020, Dr. Gottlieb has also been a frequent guest on CBS’s “Face the Nation” to discuss the COVID-19 pandemic.
Dr. Gottlieb is an aggressive advocate for advancing the health of patients, promoting healthcare access, and driving innovation. The agency’s historic and prolific advances in new policy distinguished his tenure as the FDA’s commissioner, in addition to a record-setting number of approvals of novel drugs, medical devices, and generic medicines. Under his leadership, the FDA advanced new frameworks for the modern and safe and effective oversight of gene therapies, cell based regenerative medicines, targeted drugs, and digital health devices. The FDA implemented new reforms to standardize drug reviews and make historic improvements of post market data collection and the use of real-world evidence. They promoted policies to reduce death and disease from tobacco, improve food safety, and aggressively confront addiction crises.